Company: NCNA
Filing Date: 2025-06-18
Form Type: F-3/A
Source: 0001193125-25-142565
Chunk: 16

Company: NuCana plc
Filing Date: 2025-06-18
Form: F-3/A
Chunk 16
---
,826,250 ordinary shares in lieu of ADSs, which were subsequently exercised in

12

full, and accompanying Series A ADS Purchase Warrants, or the Series A Warrants, and Series B ADS Purchase Warrants, or the Series B Warrants.

Subsequent to May 7, 2025, we issued 9,117,817,625 ordinary shares pursuant to the exercise of Series A Warrants and the exercise of all
Series B Warrants.

Ordinary Shares

As of June 16, 2025, we had issued and outstanding 9,540,891,147 ordinary shares of £0.0004 each, held by 15 shareholders of record. Each
issued ordinary share is fully paid.

Holders of ordinary shares are entitled to one vote for each share held of record on all
matters submitted to a vote of shareholders and do not have cumulative voting rights.

Any distribution made as a result of winding-up, dissolution or liquidation of our company and any dividend declared will be distributed in proportion to the number of fully paid ordinary shares held.

Deferred Shares

The deferred shares of
£0.0004 each have no dividend or voting rights and, upon a return of capital, the right only to receive the amount paid up thereon after the holders of the ordinary shares have received the amounts entitled to be paid to holders of ordinary
shares in our share capital and the further payment of £10,000,000 in respect of each ordinary share. No share certificates will be issued in respect of the deferred shares and the CREST accounts of holders of ordinary shares will not be
credited with any deferred shares.

The rights of the deferred shares are set out in new article 4.8 in the articles of association
adopted on April 23, 2025.

Deferred shares are commonly used by U.K. public companies to restructure the nominal value of their
ordinary share capital. Once created for this reason, it is not uncommon for deferred shares to be cancelled using one of the procedures available to a company under U.K. company law.

Options

We have established equity
incentive plans pursuant to which we have issued options to purchase ordinary shares to our officers, employees, consultants and directors. On June 16, 2025, our board of directors approved the grant of options to purchase an aggregate of
3,478,076,733 ordinary shares to our officers, employees, consultants and directors pursuant to our existing equity incentive plans. Upon grant of these options there